Glutathione (GSH, gamma-glutamyl-cysteinyl-glycine)
Glutathione is an antioxidant the body makes naturally in every cell. There is no UK NHS recommended supplemental amount — the body makes its own, and ordinary oral glutathione capsules are poorly absorbed (the gut breaks them down before they reach the bloodstream). Liposomal and sublingual forms are designed to get around this. If you want to support your body's natural glutathione levels, NAC (N-acetyl-cysteine) is the route most pharmacists recommend — it gives cells the building block they need to make glutathione themselves. Important: oral glutathione is NOT the antidote for paracetamol overdose. If you suspect a paracetamol overdose, call 999 or 111 immediately — the UK NHS treatment is hospital IV NAC, given by a doctor.
Camden Medicals editorial · Last reviewed 11 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Amino acid
- Typical daily dose
- Liposomal / lipid-encapsulated GSH trials have used 250–1000 mg/day across 4–12 weeks. Sublingual S-acetyl-glutathione 100–300 mg/day. Direct oral free-GSH has poor bioavailability and is not the recommended commercial form. For raising intracellular GSH, NAC at 600–1200 mg/day is the more cost-effective upstream route most pharmacology textbooks recommend.
- Top use evidence
- Strong
On this page
What it is
Glutathione is a small molecule made up of three amino acids — glutamate, cysteine, and glycine. Cells across the body make it themselves and use it as their main internal antioxidant. It also helps the liver process some medicines and break down certain compounds.
Cysteine is the bottleneck for how much glutathione your body can make — your cells can have plenty of glutamate and glycine, but if cysteine is in short supply, glutathione production slows down. This is why NAC (N-acetyl-cysteine), which delivers cysteine to cells, is often recommended as a more practical way to raise glutathione than taking glutathione directly.
The supplement forms you'll see on UK shelves:
- Liposomal glutathione — bound inside tiny lipid bubbles that
help it survive the gut. Better-absorbed than plain glutathione.
- S-acetyl-glutathione (sublingual) — a modified form designed
to absorb through the lining of the mouth, bypassing the gut.
- Reduced glutathione (plain capsules or powder) — the active
form, but poorly absorbed when taken orally. Cheapest, but
most of the dose breaks down before it reaches your bloodstream.
A note on names: oral glutathione, NAC (the cysteine precursor), and IV glutathione (the drip-clinic context) are three different things. This entry is about oral supplementation in the UK consumer context.
At a glance
- No UK NHS recommended supplemental amount. The body makes its own glutathione in every cell.
- Plain oral glutathione capsules are poorly absorbed. Liposomal and sublingual forms are designed to address this.
- NAC (N-acetyl-cysteine) is the upstream route most pharmacists recommend — it raises glutathione levels indirectly and is better-evidenced. See Camden NAC (NB-435).
- NOT the paracetamol-overdose antidote. The UK NHS treatment is hospital IV NAC. Call 999 or 111 if you suspect an overdose.
- No UK authorised health claim. "Liver detox" and "removes toxins" marketing is not permissible on UK labels.
- IV glutathione drip clinics: the UK MHRA has flagged off-label cosmetic use as a safety concern.
- Pregnancy and breastfeeding: defer — there is not enough safety data at supplement doses.
What people use it for
Adults exploring antioxidant supplementation alongside lifestyle measures, with awareness of regulatory limits
Glutathione is the principal intracellular antioxidant; supplementation rationale is to support intracellular GSH levels. Evidence for direct oral free-GSH raising plasma GSH is limited; liposomal / sublingual forms have modest trial-level evidence. UK food-supplement claim space is empty; framing is descriptive only. Most pharmacology textbooks recommend NAC (the cysteine pro-drug) as the more cost-effective upstream route.
Some evidenceLimitedAdults considering oral GSH for "detoxification" or "liver cleansing"
Not a UK-authorised food-supplement claim. The body's phase II conjugation operates continuously regardless of supplementation. Liver pathology has UK NHS pathways; self-supplementation in place of GP review is not appropriate. UK ASA / CAP guidance classifies general "removes toxins" claims as not substantiated. See myths section for the conventional framing.
Popular, not provenInsufficientAdults considering IV glutathione for skin pigmentation or "skin brightening"
Cosmetic-tier IV glutathione for melanin suppression is widely promoted in some markets. UK MHRA and other regulators have flagged off-label IV GSH cosmetic use as a safety concern. The trial evidence base for skin-lightening efficacy is limited; reported adverse events include hypersensitivity and Stevens-Johnson syndrome at high IV doses. UK NICE pathways for hyperpigmentation involve dermatology referral, topical agents (hydroquinone, retinoids under prescription), and procedural options — not IV glutathione.
Popular, not provenInsufficientAdults with paracetamol overdose
UK NHS pathway: emergency department, intravenous N-acetyl-cysteine (NAC) following the Rumack-Matthew nomogram. Oral GSH does NOT deliver this outcome. Suspected paracetamol overdose: call 999 or 111 immediately. [1,2]
Some evidenceStrong
How it works
Inside cells, glutathione works like a sponge for reactive chemicals that would otherwise damage cell structures. It donates an electron to neutralise the threat and gets used up in the process. The body then recycles it — an enzyme called glutathione reductase returns the used-up form back to the active form, so the same molecule can keep working.
Cysteine — one of the three amino acids that make up glutathione — is the rate-limiter. If a cell runs low on cysteine, it cannot make new glutathione fast enough to keep up with demand. This is the reason NAC (which delivers cysteine to cells) tends to raise glutathione levels more reliably than taking glutathione itself by mouth: glutathione capsules are largely broken down in the gut before they reach the bloodstream, but cysteine from NAC gets into cells and they make their own.
Phase II conjugation in the liver uses GSH to neutralise xenobiotics (foreign chemical compounds) by attaching them to GSH via glutathione- S-transferase enzymes. The conjugates are then excreted in bile or urine. This is the biochemical basis of the lay "detoxification" framing — but the framing on UK food-supplement labels is not permissible because (a) the body's phase II conjugation operates continuously regardless of supplementation, (b) the "toxins" referenced in marketing are rarely specified, and (c) UK ASA / CAP guidance classifies general "removes toxins" claims as not substantiated.
Paracetamol overdose mechanism is direct: at clinical-tier doses, paracetamol is mostly conjugated by phase II glucuronidation / sulfation; only a small fraction is metabolised to NAPQI (N-acetyl- p-benzoquinoneimine) by CYP2E1, and NAPQI is rapidly conjugated by GSH and excreted. At overdose, the glucuronidation pathway saturates, more paracetamol shunts to CYP2E1, NAPQI exceeds GSH conjugation capacity, and free NAPQI causes hepatocyte damage. UK NHS treatment is intravenous N-acetyl-cysteine (NAC), which delivers cysteine intracellularly to regenerate GSH. Oral GSH does not deliver this outcome — the timing of overdose treatment requires intravenous cysteine delivery.
Common myths
Myth""Glutathione removes toxins from your body""
RealityThe body''s phase II conjugation operates continuously and independently of supplementation. The lay "detoxification" / "removes toxins" framing rarely specifies which "toxins" are being targeted; UK ASA / CAP guidance classifies general "removes toxins" claims as not substantiated and not permissible on UK food- supplement labels. Liver pathology has UK NHS pathways.
Myth""Oral glutathione works as well as IV NAC for paracetamol overdose""
RealityIt does not. UK NHS treatment for paracetamol overdose is intravenous N-acetyl-cysteine (NAC) following the Rumack- Matthew nomogram, started in hospital within hours of ingestion. IV NAC delivers cysteine intracellularly to regenerate GSH; oral GSH does not deliver the same outcome at the time-critical point of overdose. Suspected paracetamol overdose is a medical emergency — call 999 or 111. [1]
Myth""All forms of oral glutathione are equally bioavailable""
RealityThey are not. Direct oral free-GSH has poor systemic bioavailability — intestinal gamma-glutamyltransferase breaks most of it down before absorption. Liposomal / lipid- encapsulated GSH and sublingual S-acetyl-glutathione have improved trial-level bioavailability. Dry-powder free-GSH capsules are the principal red flag in commercial labelling.
Myth""Glutathione lightens skin permanently""
RealityUK MHRA and other regulators have flagged off-label IV GSH cosmetic use as a safety concern. The trial evidence base for skin-lightening efficacy is limited; reported adverse events include hypersensitivity and Stevens-Johnson syndrome at high IV doses. UK NICE pathways for hyperpigmentation involve dermatology referral and prescription-grade topicals, not IV GSH cosmetic injection.
Myth""NAC is just a cheap version of glutathione — pay more for the real thing""
RealityNAC delivers cysteine — the rate-limiting amino acid for GSH synthesis — directly into the cell, where GSH is then synthesised on demand. Oral free GSH is broken down in the intestine before significant intact absorption. For raising intracellular GSH, NAC is the more cost-effective and biochemically rational route in most general supplementation contexts. Liposomal GSH addresses the bioavailability constraint but at higher cost; the price premium is not always proportionally better at the GSH-elevation endpoint.
What people say online
Glutathione is one of the highest-volume "wellness optimisation" search clusters on TikTok (#glutathione, #glutathionedrip, #liverdetox) and Reddit (r/Supplements, r/Nootropics, r/Biohackers). The dominant narratives are: (1) "master antioxidant / liver-detox" framing (no UK authorised claim; load-bearing editorial defence); (2) IV glutathione drip clinics (UK MHRA flagged safety concern); (3) skin-lightening content (high in South-East Asian + UK diaspora discourse); (4) paracetamol-overdose antidote confusion (UK NHS pathway is IV NAC, NOT oral glutathione). This section surfaces the discourse without naming individuals.
Trending claims
- TikTok + Instagram (wellness + detox content)high visibility
Claim: Glutathione detoxes your liver
Reality check: No UK or EU authorised health claim for glutathione exists. The liver does its own glutathione synthesis at appropriate levels in healthy individuals; "detoxification" is not a clinical concept the same way the marketing uses it. For documented liver-disease management, the UK pathway is GP / hepatology referral. Camden does NOT make detox claims for glutathione or NAC.
- TikTok + Instagram (drip-clinic promotional content)high visibility
Claim: IV glutathione drips are the best way to get glutathione
Reality check: UK MHRA has flagged IV cosmetic glutathione as a safety concern — Stevens-Johnson syndrome case reports + sterility / dose-control issues at non-clinical settings. UK retail drip clinics operate in a regulatory grey area. Oral liposomal glutathione (Sinha 2017, PMID 28853742) raises body GSH stores meaningfully in 1-2 weeks without the IV safety profile. The "IV is best" framing is marketing, not evidence. [7]
- TikTok (#skinlightening + Asian-beauty content)high visibility
Claim: Glutathione lightens your skin
Reality check: Trial evidence DOES exist (Wahab 2021 n=46 RCT 8 weeks combined topical + oral, PMID 33871071; Babbush 2020 review, PMID 32845595) — combination of topical + oral glutathione can reduce melanin index. However: (1) NO UK authorised health claim; (2) effect size modest; (3) IV cosmetic use MHRA-flagged. UK NHS pathway for melasma is GP / dermatology referral + prescription tyrosinase inhibitors. Skin-lightening framing carries cultural-context concerns beyond the trial evidence. [8,9]
- TikTok + Reddit (self-treatment content)medium visibility
Claim: Take glutathione for paracetamol overdose
Reality check: DANGEROUS. Paracetamol overdose is a medical emergency — call 999 or 111 immediately. UK NHS pathway is IV N-acetylcysteine (NAC) administered in hospital, NOT oral glutathione. Oral glutathione is poorly absorbed AND systemic uptake is too slow for acute overdose. Even oral NAC at home is not the right pathway — the antidote is hospital IV NAC.
Where the conversation lives
- TikTok hashtags: #glutathione, #glutathionedrip, #liverdetox, #masterantioxidant, #ivglutathione, #skinlightening
- Reddit subs: r/Supplements, r/Nootropics, r/Biohackers, r/SkincareAddiction, r/AsianBeauty
- Forums: Examine.com (paid analysis), Lab-tested supplement reviews
Questions people are searching
- Does glutathione actually work as a supplement?
- IV glutathione drip — is it safe and worth it?
- Liposomal vs S-acetyl vs reduced glutathione — which is best?
- Can glutathione lighten my skin?
- NAC or glutathione — which should I take?
Who drives the discourse: The discourse is driven by three influencer classes: wellness / biohacker creators (highest reach, often promote IV drips + detox framing without UK MHRA context); functional-medicine practitioner creators (more evidence-anchored on bioavailability forms); and beauty / aesthetic-clinic creators (skin-lightening content, IV drip promotion). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Glutathione (GSH, gamma-glutamyl-cysteinyl-glycine). Each answer is editorial and links to its evidence in the Sources list below.
What is the difference between glutathione and NAC?
Glutathione (GSH) is the antioxidant tripeptide your cells use directly. NAC (N-acetyl-cysteine) is the cysteine pro-drug your cells use to synthesise GSH — cysteine is the rate-limiting amino acid for GSH synthesis. For most supplementation contexts most pharmacology textbooks recommend NAC because (a) NAC is cheaper, (b) NAC delivers cysteine intracellularly where GSH synthesis happens, and (c) oral free GSH has poor systemic bioavailability. Liposomal GSH and sublingual S-acetyl- glutathione address the bioavailability constraint but are commercially more expensive.
Is glutathione a "detoxification" supplement?
The body''s phase II conjugation pathway uses GSH to neutralise xenobiotics (foreign chemical compounds) and excrete them via bile or urine. This continuous biochemical process operates regardless of supplementation. The lay framing of "detoxification" supplements rarely specifies which "toxins" are being removed, and UK ASA / CAP guidance classifies general "removes toxins" claims as not substantiated. Liver pathology has UK NHS pathways; self-supplementation in place of GP review is not appropriate.
Should I take glutathione or NAC for paracetamol overdose?
Neither — call 999 or 111 immediately. UK NHS treatment for paracetamol overdose is intravenous N-acetyl-cysteine (NAC) following the Rumack-Matthew nomogram, administered in hospital within hours of ingestion ideally. Oral glutathione is NOT this pathway. Suspected paracetamol overdose is a medical emergency — the IV-NAC delivery route is what the BNF acetylcysteine monograph specifies. [1,2]
Does liposomal glutathione actually work?
Liposomal and lipid-encapsulated GSH formulations have modest trial-level evidence for raising plasma and lymphocyte GSH after 4–12 weeks of 250–1000 mg/day supplementation. Whether the price premium over NAC delivers proportionally better intracellular GSH levels is unclear; the cysteine-delivery argument favours NAC. For most consumers most pharmacology textbooks recommend NAC at 600–1200 mg/day as the more cost-effective route.
Is IV glutathione safe for skin lightening?
UK MHRA and other regulators have flagged off-label IV glutathione cosmetic use as a safety concern. Reported adverse events at high IV doses include hypersensitivity, kidney impairment, and Stevens-Johnson syndrome. UK NICE pathways for hyperpigmentation involve dermatology referral, prescription topicals (hydroquinone, retinoids), and procedural options under specialist supervision — not IV glutathione cosmetic injection.
Can I take glutathione in pregnancy?
Defer. There is limited human pregnancy safety data for oral glutathione supplementation. Talk to your midwife or GP before starting if you are pregnant or planning conception.
UK regulatory landscape
UK regulatory tier: Food supplement
Oral glutathione is regulated under the UK Food Supplements (England) Regulations 2003 + assimilated EU Food Supplements Directive 2002/46/EC. NO authorised UK health claim exists for glutathione under the GB Nutrition and Health Claims (NHC) Register — descriptive marketing only is permissible. IV glutathione (cosmetic / wellness drip-clinic context) is flagged as a UK MHRA safety concern: Stevens-Johnson syndrome case reports + sterility / dose-control issues at non-clinical settings. Topical glutathione (cosmetic skin-lightening) is regulated under UK Cosmetic Products Regulation — no UK authorised health claim. Paracetamol overdose is a UK NHS A&E pathway via IV NAC (not oral glutathione).
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing as "detox" or "liver cleansing" or "removes toxins" | Crosses to medicinal claims; ASA / CAP Code §15 enforcement. There is no UK authorised health claim — marketing under this framing is non-compliant. |
| IV cosmetic / wellness-drip-clinic use | UK MHRA safety advisory territory. Stevens-Johnson syndrome case reports. Drip clinics operate in regulatory grey area; some require CQC registration depending on tier of procedure. |
| Marketing as paracetamol-overdose antidote | DANGEROUS — UK NHS A&E pathway is IV NAC, NOT oral glutathione. Self-treatment framing creates patient-safety risk; criminal liability if such marketing causes harm. |
| Marketing as skin-lightening agent | UK Cosmetic Products Regulation territory if topical; supplements claim if oral. No UK authorised claim. Cultural-context concerns beyond regulatory framework. |
Permitted claims
NO UK authorised health claim. Permitted marketing: descriptive ingredient claims, antioxidant-substance descriptive framing, transparent ingredient-form labelling. NOT permitted: detox / cleansing / liver-disease / cancer / skin-lightening / overdose antidote / lifespan-extension claims.
Cross-jurisdiction note
US glutathione regulation: widely available OTC supplement under DSHEA; IV cosmetic drip clinics common in US but regulatory framework differs. EU + UK have stricter health- claim regulation. UK consumers should not assume US-clinic promotion (especially IV) translates to UK retail / safety context.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Plasma GSH elevation — oral supplementation
LimitedEvidencelimitedDirect oral free-GSH has poor systemic bioavailability; intestinal gamma-glutamyltransferase breaks down most ingested GSH before absorption. Liposomal and lipid-encapsulated forms (e.g. Setria® liposomal GSH) report modest trial-level increases in plasma GSH and lymphocyte GSH after 4–12 weeks of supplementation at 250–1000 mg/day. Whether the supplementation outperforms equimolar NAC dosing on the same endpoint is unclear; pharmacology textbooks generally favour NAC as the more cost-effective cysteine-delivery route.
Paracetamol overdose — intravenous NAC pathway
StrongEvidencestrongUK NHS pathway is intravenous N-acetyl-cysteine following the Rumack-Matthew nomogram, started within 8 hours of ingestion ideally and effective up to 24 hours and beyond in some protocols. Mechanism: IV NAC delivers cysteine intracellularly to regenerate GSH, which conjugates the toxic NAPQI metabolite of paracetamol. Oral glutathione is NOT this pathway. Suspected paracetamol overdose is a medical emergency. [1,2]
Skin pigmentation reduction (oral / IV GSH cosmetic use)
InsufficientEvidenceinsufficientCosmetic-tier marketing in some markets promotes oral or IV glutathione for skin lightening via melanin suppression. The trial evidence base is limited; UK MHRA and other regulators have flagged off-label IV GSH cosmetic use as a safety concern. UK NICE pathways for hyperpigmentation involve dermatology referral, prescription topicals (hydroquinone, retinoids), and procedural options.
Liver disease (NAFLD, alcoholic liver disease) — adjunct
LimitedEvidencelimitedSmall trials of oral and IV GSH in non-alcoholic fatty liver disease and chronic hepatitis report modest improvements in liver-enzyme markers (ALT, AST). UK NICE NG49 (non-alcoholic fatty liver disease) does not list GSH as a recommended intervention. NAC has more comprehensive trial coverage in liver-disease contexts. [3]
Parkinson's disease — adjunct
LimitedEvidencelimitedSmall trials of intranasal and IV glutathione in Parkinson''s disease have reported some symptom-score improvements; sample sizes are very small. UK NICE NG71 (Parkinson''s disease in adults) does not list GSH as a recommended adjunct. Specialist Parkinson''s management is the appropriate pathway, not self-supplementation. [4]
Clinical literature review
The oral-glutathione bioavailability literature centred on the Penn State Cancer Institute / Richie group's two RCTs is the strongest body of evidence for oral supplementation raising systemic GSH stores. Richie et al. 2014 (Eur J Nutr, PMID 24791752) ran a 6-month double-blind placebo-controlled RCT of oral GSH at 250 or 1000 mg/day in 54 healthy adults — at 6 months, blood/erythrocyte/plasma/lymphocyte GSH rose 30-35% in the high-dose group, with 260% rise in buccal cells. The shorter-duration liposomal follow-up (Sinha et al. 2017, Eur J Clin Nutr, PMID 28853742) tested liposomal GSH 500-1000 mg/day in 12 healthy adults — whole blood +40%, plasma +28%, PBMCs +100% in 1-2 weeks; NK cytotoxicity +400%. For skin-lightening (a major TikTok / Reddit search cluster), Wahab et al. 2021 (Int J Dermatol, PMID 33871071) RCT n=46 of topical+oral glutathione 8 weeks shows the combination reduces melanin index; Babbush et al. 2020 (J Drugs Dermatol, PMID 32845595) reviews antioxidants for melasma including glutathione. The structural weaknesses are: (a) most trials are small (n<60); (b) NO UK / EU authorised health claim for glutathione exists; (c) IV cosmetic glutathione is UK MHRA-flagged for safety.
Key trials
Richie JP et al. · 2014 · Eur J Nutr · PMID 24791752
Finding: Oral GSH at 250 or 1000 mg/day vs placebo in non-smoking healthy adults. At 6 months, GSH stores rose 30-35% in erythrocytes/plasma/lymphocytes and 260% in buccal-mucosal cells in the high-dose group (p<0.05); 17-29% rises at the low dose. Reduction in oxidised:reduced GSH ratio in whole blood; NK cytotoxicity >2x in high-dose group at 3 months. Effect reverted after 1-month washout — supplementation must be continuous.
Relevance: Foundational long-duration RCT establishing oral GSH (not liposomal) bioavailability in humans. The 6-month duration + dose-response signal makes this the most-cited UK- relevant trial for general glutathione supplementation.
Sinha R et al. · 2017 · Eur J Clin Nutr · PMID 28853742
Finding: Oral liposomal GSH 500 or 1000 mg/day in 12 healthy adults. GSH up after 1 week, peaking at 2 weeks: whole blood +40%, erythrocytes +25%, plasma +28%, PBMCs +100% (all p<0.05). Oxidative stress biomarkers fell: 8-isoprostane -35%, oxidised:reduced GSH ratio -20%. NK cytotoxicity +400% by 2 weeks; lymphocyte proliferation +60%. No dose-group difference (statistical power limited).
Relevance: Establishes faster bioavailability + immune-function effects for the liposomal formulation. Smaller n than Richie 2014 but supports the liposomal-superiority narrative seen in UK consumer marketing — though direct head-to-head trials vs free GSH are absent.
Wahab S et al. · 2021 · Int J Dermatol · PMID 33871071
Finding: Combined topical + oral glutathione vs topical glutathione alone vs oral glutathione alone vs placebo (split-face + oral placebo design). Combination group had significantly lower melanin index (MI) and L* score vs placebo (p<0.05). Combination superior to monotherapy for skin-lightening endpoints.
Relevance: Direct trial evidence for the TikTok / Reddit "skin lightening" search cluster. UK regulatory context: there is NO authorised UK health claim for glutathione skin- lightening. IV cosmetic use is UK MHRA-flagged for safety concerns. This trial covers the topical + oral context only (not IV).
Systematic reviews
- pmid:32845595
Babbush 2020 J Drugs Dermatol review of antioxidants for melasma (vitamin C, azelaic acid, cysteamine, glutathione, carotenoids). Promising evidence for topical / oral / IV preparations, but no universally efficacious therapy. Combination approach typical.
Evidence quality summary
Oral glutathione raising body GSH stores — MODERATE certainty (Richie 2014 6-month RCT n=54). Liposomal glutathione raising GSH stores faster — LIMITED certainty (Sinha 2017 n=12 pilot only). Skin-lightening — MODERATE certainty for topical + oral combination (Wahab 2021 n=46). Detox / liver-cleansing claims — INSUFFICIENT certainty (no trial evidence; no UK authorised claim). Paracetamol-overdose antidote — NOT a glutathione indication; UK NHS pathway is IV NAC. Pregnancy supplementation — INSUFFICIENT human data (precautionary defer).
Known gaps
- No head-to-head RCTs of free oral GSH vs liposomal GSH at matched dose / duration.
- No long-term (>12 month) outcome data.
- Most trials are US (Penn State Richie group) or Indonesian (Wahab dermatology); UK-specific clinical-outcome data absent.
- No pregnancy / lactation safety RCTs at supplementation doses.
- Trial endpoints are typically blood GSH stores or oxidative-stress biomarkers; clinical-outcome trials for specific UK conditions (NAFLD, COPD) are limited.
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Oral glutathione at standard supplement doses is generally well-tolerated. The principal regulatory concern is off-label IV cosmetic use (UK MHRA flagged safety concern). Pregnancy and breastfeeding: defer. Suspected paracetamol overdose is a medical emergency — call 999 or 111; oral glutathione is NOT the antidote.
Talk to your pharmacist or GP first if you:
- You take chemotherapy — some evidence of antagonism with certain regimens; defer to oncologist.
- You take any prescription anti-asthma medication — limited interaction data; talk to prescriber.
- You have asthma — oral GSH can occasionally trigger bronchospasm in cysteine-sensitive individuals (rare).
- You are pregnant, breastfeeding, or trying to conceive — defer.
- You have a paracetamol overdose — call 999 or 111. UK NHS pathway is IV NAC, not oral GSH.
Common side effects: Generally none at standard food-supplement doses. Mild GI upset occasionally reported.
Pregnancy and breastfeeding
Glutathione is endogenously synthesised in the body and present naturally in food (cooked vegetables, animal proteins). At dietary intake amounts, no specific pregnancy concern. At supplementation doses, insufficient human safety data — UK precautionary defer position recommended. Talk to your midwife or GP if you are pregnant or planning conception.
Same precautionary defer position as pregnancy. Insufficient human safety data at supplementation doses. Talk to your midwife or GP about whether continuing dietary glutathione intake (no concern) vs supplementation (defer) is appropriate for your context.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Active chemotherapy without oncologist review (potential antagonism with some regimens).
- IV cosmetic use is flagged as a safety concern by UK MHRA — not a UK retail context.
Drug interactions
Chemotherapy regimens (cisplatin, carboplatin, alkylating agents) · high
Effect: Mixed evidence on whether antioxidant supplementation (including glutathione) interferes with chemotherapy efficacy. Some regimens rely on oxidative stress for tumour cell killing; supplementation timing matters.
Mechanism: GSH is the cell's principal scavenger of cytotoxic ROS; the same property that confers protection in healthy cells may protect tumour cells under chemotherapy. Specialist oncology context.
Action: Talk to your oncologist or prescribing clinician before starting or continuing glutathione (or NAC) during active chemotherapy.
Source: BNF cancer chemotherapy + clinical oncology consensus
Nitroglycerin and other organic nitrates · low
Effect: High-dose oral GSH may slightly modify nitrate effects (nitrate tolerance, cardiovascular response). Modest clinical impact; co-monitoring prudent.
Mechanism: Glutathione affects vasodilation pathways through S-nitrosothiol formation; theoretical interaction with nitrate vasodilation.
Action: Tell your GP or prescriber if you take oral or transdermal nitrates and start glutathione supplementation.
Source: BNF nitrate monograph + cardiology consensus
Cisplatin (specialist oncology context) · high
Effect: Specific evidence: cisplatin nephrotoxicity may be partially protected by GSH supplementation in some trial protocols. This is a specialist oncology decision, NOT a self- supplementation context.
Mechanism: Cisplatin nephrotoxicity is partly mediated by renal-cell oxidative stress; GSH supplementation has been studied as protective adjunct in clinical oncology.
Action: Talk to your oncologist or specialist before any glutathione supplementation during cisplatin therapy — protocol-specific decision, not consumer-led.
Source: Clinical oncology trial literature + BNF cisplatin
Asthma medications (in cysteine-sensitive individuals) · medium
Effect: Oral GSH (and the upstream NAC) can occasionally trigger bronchospasm in cysteine-sensitive asthma patients. Rare but reported.
Mechanism: Cysteine sulfhydryl group reactivity; some asthma phenotypes show airway hyper-reactivity to thiol compounds.
Action: Tell your asthma clinician or pharmacist if you start glutathione or NAC and develop new wheeze or bronchospasm.
Source: BNF NAC monograph + respiratory consensus
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Generally none at standard food-supplement doses (250–1000 mg/day liposomal).
- Mild GI upset — occasionally reported; reduced by taking with food.
Rare side effects
- Bronchospasm — rare; cysteine-related sensitivity in some asthma patients.
- Hypersensitivity reactions — uncommon; reported with IV high-dose use.
- Stevens-Johnson syndrome — case reports with IV cosmetic-use high doses.
How to take it
- Typical supplemental range
- Liposomal / lipid-encapsulated GSH trials have used 250–1000 mg/day across 4–12 weeks. Sublingual S-acetyl-glutathione 100–300 mg/day. Direct oral free-GSH has poor bioavailability and is not the recommended commercial form. For raising intracellular GSH, NAC at 600–1200 mg/day is the more cost-effective upstream route most pharmacology textbooks recommend.
- Timing
- Liposomal GSH: typically morning, with or without food. Sublingual: between meals. NAC: with food to reduce GI upset.
How to spot quality
Look for
- Form named explicitly on the label — liposomal GSH, S-acetyl-glutathione, or reduced GSH (specifying the form).
- Setria® branded liposomal GSH (Kyowa Hakko) for documented sourcing chain, when applicable.
- Lipid-encapsulation technology disclosed (phosphatidylcholine, sunflower lecithin liposome).
- Reduced (GSH) vs oxidised (GSSG) form distinction at HPLC assay level on CoA.
- GMP-certified manufacture; reputable supplier chain.
- CoA available on request; GSH assay (HPLC) confirms identity and reduced-form content.
- Cold-chain handling for liposomal forms (heat / oxidation degradation risk).
- Excipient list disclosed.
Red flags
- Form not declared — "glutathione 500 mg" without specifying liposomal / sublingual / dry-powder.
- Dry-powder free-GSH oral capsules (poor bioavailability — intestinal breakdown).
- "Detoxification" / "liver cleansing" / "removes toxins" framing.
- Skin-lightening / "skin brightening" / IV-glutathione promotion (UK MHRA flagged safety concern).
- Paracetamol-overdose substitution claims (UK NHS pathway is IV NAC).
- Doses above 2 g per serving in a general-supplementation context (without trial-protocol or clinical rationale).
- Marketing that frames oral GSH as universally superior to NAC without addressing the bioavailability constraint.
Where Camden lands · gap declared
Camden has no glutathione SKU at the time of writing. If Camden formulates with Setria® branded liposomal glutathione in a lipid-encapsulated soft-gel, the SKU would be a candidate for the Aurifera tier per the 2026-05-10 -fera tier rule (named licensed clinical-grade ingredient). Camden currently directs consumers to NAC (NB-435) as the cost-effective upstream route for raising intracellular GSH; this entry exists to complete the methionine → cysteine → NAC → GSH cluster narrative and to provide defensive content on the "detoxification" online myth.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
N-Acetyl Cysteine (NAC)
Insufficient evidenceUpstream / downstream cluster pair — NAC delivers cysteine, the rate-limiting amino acid for GSH synthesis. Combining NAC with oral GSH is conceptually duplicative (both routes raise intracellular GSH); most pharmacology textbooks recommend NAC alone for cost-effectiveness.
NAC is deacetylated to cysteine, which the cell uses (via glutamate cysteine ligase and glutathione synthetase) to synthesise GSH. Direct oral free-GSH has poor systemic bioavailability (intestinal GGT breakdown); liposomal forms address this constraint. The two routes converge on the same intracellular GSH endpoint.
Evidence: NAC has stronger trial-level evidence than direct oral GSH for raising intracellular GSH. Combining the two has not been the subject of pivotal trials.
Doses studied: Not a typical commercial combination (one route per supplement). Where stacked: NAC 600 mg + liposomal GSH 250 mg per serving in some "GSH support" formulations.
Found in Camden: Purifera™ NAC N-Acetyl-Cysteine 600mg 120 Capsules
Alpha Lipoic Acid (ALA / thioctic acid)
Limited evidenceAntioxidant cluster pair — alpha-lipoic acid (and dihydrolipoic acid) helps regenerate GSH from GSSG and recycles vitamin C and vitamin E. The combination is mechanistically additive in narrative terms; UK food-supplement co-claim is not authorised.
Alpha-lipoic acid is reduced to dihydrolipoic acid (DHLA), which can directly reduce GSSG back to GSH and also recycle vitamin C (ascorbate radical → ascorbate) and vitamin E (alpha-tocopheryl radical → alpha-tocopherol). The "antioxidant network" framing that includes ALA + GSH + vitamin C + vitamin E is mechanistically well-characterised but does not produce a UK-authorised co-claim.
Evidence: Mechanism is well-characterised; clinical-outcome benefit from the combination is not established in pivotal trials.
Doses studied: Liposomal GSH 250 mg + alpha-lipoic acid 200–600 mg per serving in antioxidant-stack formulations.
Vitamin C
Limited evidenceAntioxidant network pair — vitamin C reduces GSSG back to GSH non-enzymatically and shares lipid-phase / aqueous-phase antioxidant labour. Combination is mechanistically rational; UK food-supplement co-claim is not authorised for the pair (vitamin C has its own authorised claims at NRV thresholds).
Vitamin C (ascorbate) can directly reduce GSSG to GSH non- enzymatically. In the antioxidant network framing, vitamin C operates in the aqueous phase, vitamin E in the lipid phase, and GSH in the intracellular cytoplasm; the three regenerate each other through coupled redox cycles.
Evidence: Mechanism is well-characterised; clinical-outcome benefit from combining oral vitamin C with oral GSH (vs vitamin C alone) is not established.
Doses studied: Liposomal GSH 250 mg + vitamin C 500–1000 mg per serving in antioxidant-stack formulations.
Selenium
Limited evidenceCofactor pair — glutathione peroxidase (GPx) is the selenoprotein that uses GSH to neutralise hydrogen peroxide and lipid peroxides. Adequate selenium status is the rate-limiter for GPx activity.
Glutathione peroxidase is one of ~25 known human selenoproteins. Its active site contains a selenocysteine residue. Selenium deficiency reduces GPx activity directly, regardless of GSH availability. Conversely, abundant GSH without adequate selenium is functionally limited at the GPx step. Camden NB-550 supplies selenium L-selenomethionine 200 µg per capsule.
Evidence: Selenium-cofactor role for GPx is well-established. Selenium deficiency is rare in the UK general population at standard dietary intake.
Doses studied: Selenium 50–200 µg + GSH formulation per serving in antioxidant-stack supplements. Camden NB-550 supplies the selenium side.
Found in Camden: Purifera™ Selenium 200µg L-Selenomethionine 120 Capsules
Verifera™ editorial perspective
Why it matters. Glutathione is one of the highest-volume "detox / liver-cleanse" search clusters in UK consumer wellness — driven by social-media content far more than by authorised UK health claims (there are none). The Verifera editorial position is that this entry should be the UK-anchored reference that disambiguates the bioavailability reality (oral free-GSH is poorly absorbed; liposomal / S-acetyl forms are different), debunks the "detox" framing, and anchors paracetamol-overdose context to the UK NHS IV NAC pathway (NOT oral glutathione).
Where Camden lands. Camden Medicals does NOT currently retail a glutathione SKU. Camden retails NAC (NB-435) as the cost-effective upstream cysteine pro-drug for raising intracellular GSH. This entry exists to complete the methionine → cysteine → NAC → GSH cluster and provide defensive content on the detox / skin-lightening online myths. A future Aurifera-tier candidate with Setria®- branded liposomal GSH is plausible but not currently formulated.
If you want to explore further. For UK consumers researching glutathione: NHS general nutrition and pregnancy pages are entry points. For paracetamol-overdose concerns (the most-load-bearing safety context): call 999 or 111 — UK NHS pathway is IV NAC, not oral glutathione, ever. For oxidative-stress concerns from a specific condition (cystic fibrosis, COPD), the appropriate pathway is GP referral to specialist. Talk to your pharmacist or GP about whether NAC (Camden NB-435) is a more cost-effective starting point than liposomal glutathione.
How this entry was researched
Authoritative sources consulted:
- NHS general nutrition + pregnancy pages
- NICE CKS Paracetamol poisoning
- UK NHS Toxbase paracetamol pathway (NAC IV antidote)
- GB Nutrition and Health Claims (NHC) Register — glutathione has NO authorised claim
- UK Cosmetic Products Regulation (topical glutathione context)
- UK MHRA cosmetic-IV safety advisories
- PubMed (via E-utilities MCP)
PubMed search terms:
oral glutathione supplementation bioavailability clinical trialRichie glutathione oral supplementation randomizedliposomal glutathione bioavailability humans clinicalSinha glutathione liposomal supplementation oxidative stressglutathione skin lightening topical clinical trial
Literature search date: 2026-05-11
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.